Stockreport

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]

Cardiff Oncology, Inc.  (CRDF) 
PDF 21min Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estima [Read more]